Therapeutic proteins immunogenicity: a peptide point of view
Protein therapeutics are extensively used in the treatment of autoimmune diseases, but a subset of patients appears to be refractory to these treatments, mainly due to the development of an immune response to the drug. A better understanding of the mechanism underlying the therapeutic drug’s failure...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Open Exploration
2023-10-01
|
| Series: | Exploration of Drug Science |
| Subjects: | |
| Online Access: | https://www.explorationpub.com/uploads/Article/A100825/100825.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1825199591995211776 |
|---|---|
| author | Feliciana Real-Fernandez Fosca Errante Andrea Di Santo Anna Maria Papini Paolo Rovero |
| author_facet | Feliciana Real-Fernandez Fosca Errante Andrea Di Santo Anna Maria Papini Paolo Rovero |
| author_sort | Feliciana Real-Fernandez |
| collection | DOAJ |
| description | Protein therapeutics are extensively used in the treatment of autoimmune diseases, but a subset of patients appears to be refractory to these treatments, mainly due to the development of an immune response to the drug. A better understanding of the mechanism underlying the therapeutic drug’s failure becomes fundamental for the development of new and more effective treatments. Unfortunately, there are few cases where the exact mechanisms through which drugs bypass immunological tolerance and provoke immunogenicity have been studied. In this context, peptide epitope identification gained increasing importance in investigating the molecular mechanism of therapeutic drug’s immune responses. Despite peptide identification and use to monitor anti-drug antibody (ADA) profiles is a promising research field, their use is far away from a wide application both at the research and at the commercial level. Herein it is reported a compilation of studies in which peptides are directly involved in anti-drug immune responses, becoming the molecular key step for a better understanding of refractory reactions in therapeutic drugs. An overview on T-cell and B-cell peptide recognition is given, showing the growing potential and advantages of peptides when used in the field of refractoriness to drugs. This review includes studies describing antigenic peptides that enable enhanced ADA detection directly in patients’ sera, as well as the proof of concept that asses the use of peptides instead of proteins, to facilitate the identification of neutralizing ADA. |
| format | Article |
| id | doaj-art-9a6eccbc227e4804b10ad234e46d166f |
| institution | Kabale University |
| issn | 2836-7677 |
| language | English |
| publishDate | 2023-10-01 |
| publisher | Open Exploration |
| record_format | Article |
| series | Exploration of Drug Science |
| spelling | doaj-art-9a6eccbc227e4804b10ad234e46d166f2025-02-08T03:49:04ZengOpen ExplorationExploration of Drug Science2836-76772023-10-011537738710.37349/eds.2023.00025Therapeutic proteins immunogenicity: a peptide point of viewFeliciana Real-Fernandez0https://orcid.org/0000-0001-5747-2285Fosca Errante1https://orcid.org/0000-0001-7790-9886Andrea Di Santo2https://orcid.org/0000-0003-3075-8878Anna Maria Papini3https://orcid.org/0000-0002-2947-7107Paolo Rovero4https://orcid.org/0000-0001-9577-5228Institute of Chemistry of Organometallic Compounds (ICCOM), National Research Council of Italy (CNR), 50019 Sesto Fiorentino, ItalyInterdepartmental Research Unit of Peptide and Protein Chemistry and Biology, Department of NeuroFarBa, University of Florence, 50019 Sesto Fiorentino, ItalyInterdepartmental Research Unit of Peptide and Protein Chemistry and Biology, Department of NeuroFarBa, University of Florence, 50019 Sesto Fiorentino, ItalyInterdepartmental Research Unit of Peptide and Protein Chemistry and Biology, Department of Chemistry “Ugo Schiff”, University of Florence, 50019 Sesto Fiorentino, ItalyInterdepartmental Research Unit of Peptide and Protein Chemistry and Biology, Department of NeuroFarBa, University of Florence, 50019 Sesto Fiorentino, ItalyProtein therapeutics are extensively used in the treatment of autoimmune diseases, but a subset of patients appears to be refractory to these treatments, mainly due to the development of an immune response to the drug. A better understanding of the mechanism underlying the therapeutic drug’s failure becomes fundamental for the development of new and more effective treatments. Unfortunately, there are few cases where the exact mechanisms through which drugs bypass immunological tolerance and provoke immunogenicity have been studied. In this context, peptide epitope identification gained increasing importance in investigating the molecular mechanism of therapeutic drug’s immune responses. Despite peptide identification and use to monitor anti-drug antibody (ADA) profiles is a promising research field, their use is far away from a wide application both at the research and at the commercial level. Herein it is reported a compilation of studies in which peptides are directly involved in anti-drug immune responses, becoming the molecular key step for a better understanding of refractory reactions in therapeutic drugs. An overview on T-cell and B-cell peptide recognition is given, showing the growing potential and advantages of peptides when used in the field of refractoriness to drugs. This review includes studies describing antigenic peptides that enable enhanced ADA detection directly in patients’ sera, as well as the proof of concept that asses the use of peptides instead of proteins, to facilitate the identification of neutralizing ADA.https://www.explorationpub.com/uploads/Article/A100825/100825.pdfpeptidesanti-drug antibodiesimmune responsepeptide epitopestherapeutics |
| spellingShingle | Feliciana Real-Fernandez Fosca Errante Andrea Di Santo Anna Maria Papini Paolo Rovero Therapeutic proteins immunogenicity: a peptide point of view Exploration of Drug Science peptides anti-drug antibodies immune response peptide epitopes therapeutics |
| title | Therapeutic proteins immunogenicity: a peptide point of view |
| title_full | Therapeutic proteins immunogenicity: a peptide point of view |
| title_fullStr | Therapeutic proteins immunogenicity: a peptide point of view |
| title_full_unstemmed | Therapeutic proteins immunogenicity: a peptide point of view |
| title_short | Therapeutic proteins immunogenicity: a peptide point of view |
| title_sort | therapeutic proteins immunogenicity a peptide point of view |
| topic | peptides anti-drug antibodies immune response peptide epitopes therapeutics |
| url | https://www.explorationpub.com/uploads/Article/A100825/100825.pdf |
| work_keys_str_mv | AT felicianarealfernandez therapeuticproteinsimmunogenicityapeptidepointofview AT foscaerrante therapeuticproteinsimmunogenicityapeptidepointofview AT andreadisanto therapeuticproteinsimmunogenicityapeptidepointofview AT annamariapapini therapeuticproteinsimmunogenicityapeptidepointofview AT paolorovero therapeuticproteinsimmunogenicityapeptidepointofview |